satavaptan has been researched along with Liver Cirrhosis in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aagaard, NK; Gantzel, RH; Grønbaek, H; Jepsen, P; Vilstrup, H; Watson, H | 1 |
| Jepsen, P; Vilstrup, H; Watson, H; Wong, F | 1 |
| Andersen, PK; Bossen, L; Dam, G; Jepsen, P; Vilstrup, H; Watson, H | 1 |
| Ginès, P; Guevara, M; Vilstrup, H; Watson, H | 1 |
| Córdoba, J; Ginès, P; Jepsen, P; Vilstrup, H; Watson, H; Wong, F | 1 |
| Kwo, PY | 1 |
| Andersen, PK; Jepsen, P; Vilstrup, H; Watson, H | 1 |
| Bossen, L; Jepsen, P; Krag, A; Vilstrup, H; Watson, H | 1 |
| del Arbol, LR; Ginès, P; Milutinovic, S; Olteanu, D; Watson, H; Wong, F | 1 |
| Ginès, P; Guevara, M | 1 |
| Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP | 1 |
| Angeli, P; Bernardi, M; Gines, P; Gow, P; Horsmans, Y; Minini, P; Watson, H; Wong, F | 1 |
| Accordino, S; Cazzaniga, M; Salerno, F | 1 |
| Villabona, C | 1 |
| Er, F; Fuhr, U; Gassanov, N; Nia, AM; Semmo, M; Semmo, N | 1 |
| Badalamenti, S; Bernardi, M; Gerbes, A; Ginès, P; Vilstrup, H; Watson, H; Wong, F | 1 |
| Dahl, E; Gluud, LL; Kimer, N; Krag, A | 1 |
| Ferguson, JW; Hayes, PC; Newby, DE; Therapondos, G | 1 |
| Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
| Jiménez, W | 1 |
8 review(s) available for satavaptan and Liver Cirrhosis
| Article | Year |
|---|---|
Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Spiro Compounds; Survival Analysis | 2013 |
Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Sodium; Spiro Compounds | 2008 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Biological; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan; Water-Electrolyte Balance | 2011 |
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzamides; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Sodium; Spiro Compounds; Tolvaptan; Treatment Outcome | 2012 |
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Diuretics; Heart Failure; Homeostasis; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Animal; Morpholines; Piperidines; Pyrroles; Quinolones; Rats; Spiro Compounds; Vasopressins | 2003 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
[Aquaretic agents].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporin 6; Aquaporins; Ascites; Benzeneacetamides; Body Water; Demeclocycline; Diuresis; Diuretics; Humans; Kidney Tubules, Collecting; Liver Cirrhosis; Liver Cirrhosis, Experimental; Morpholines; Pyrrolidines; Rats; Receptors, Opioid, kappa; Receptors, Vasopressin; Spiro Compounds; Vasopressins | 2002 |
8 trial(s) available for satavaptan and Liver Cirrhosis
| Article | Year |
|---|---|
Development and validation of the Cirrhotic Ascites Severity model-A patient-reported outcome-based model to predict 1-year mortality.
Topics: Ascites; Diuretics; End Stage Liver Disease; Humans; Liver Cirrhosis; Patient Reported Outcome Measures; Severity of Illness Index; Sodium | 2022 |
Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites.
Topics: Acute Kidney Injury; Aged; Ascites; Creatinine; Diuretics; Female; Humans; Internationality; Liver Cirrhosis; Male; Middle Aged; Morpholines; Paracentesis; Prognosis; Proportional Hazards Models; Severity of Illness Index; Spiro Compounds | 2018 |
Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hepatic Encephalopathy; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Spiro Compounds; Survival Rate; Time Factors | 2015 |
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Topics: Adrenergic beta-Antagonists; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Spiro Compounds | 2016 |
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Blood Circulation; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyponatremia; Kidney; Liver Cirrhosis; Male; Middle Aged; Morpholines; Renin-Angiotensin System; Sodium; Spiro Compounds; Treatment Outcome | 2008 |
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Method; Drug Combinations; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prospective Studies; Spiro Compounds; Spironolactone; Treatment Outcome | 2010 |
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Creatinine; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Morpholines; Paracentesis; Secondary Prevention; Spiro Compounds; Spironolactone; Thirst; Treatment Outcome | 2010 |
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Middle Aged; Morpholines; Proportional Hazards Models; Secondary Prevention; Spiro Compounds; Treatment Outcome | 2012 |
4 other study(ies) available for satavaptan and Liver Cirrhosis
| Article | Year |
|---|---|
Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Bacterial Infections; Female; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Peritonitis; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spiro Compounds; Time Factors; Treatment Outcome | 2019 |
Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.
Topics: Cognition; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Morpholines; Sodium; Spiro Compounds; Treatment Outcome | 2019 |
Management of hyponatremia in clinical hepatology practice.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drinking Behavior; Fluid Therapy; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Spiro Compounds; Tolvaptan | 2014 |
May vaptans contribute to the treatment of refractory ascites?
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Diuretics; Dose-Response Relationship, Drug; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Paracentesis; Spiro Compounds; Spironolactone; Treatment Outcome | 2010 |